Evidence map›Paper›PMID 36077082›Full record

ArticleInternational journal of molecular sciences2022

Combined Treatment with Curcumin and Ferulic Acid Suppressed the Aβ-Induced Neurotoxicity More than Curcumin and Ferulic Acid Alone.

Hideaki Ohashi, Mayumi Tsuji, Tatsunori Oguchi, Yutaro Momma, Tetsuhito Nohara, Naohito Ito, Ken Yamamoto, Miki Nagata, Atsushi Michael Kimura, Yuji Kiuchi and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Therapeutic Candidates for Alzheimer's Disease: Saponins.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hideaki OhashiDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Mayumi TsujiPharmacological Research Center, Showa University, Tokyo 142-8555, Japan.
Tatsunori OguchiDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Yutaro MommaDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Tetsuhito NoharaDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Naohito ItoDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Ken YamamotoDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Miki NagataDepartment of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo 142-8555, Japan.ORCID 0000-0002-8288-5935
Atsushi Michael KimuraDivision of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Yuji KiuchiDivision of Medical Pharmacology, Department of Pharmacology, School of Medicine, Showa University, Tokyo 142-8555, Japan.
Kenjiro OnoDepartment of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8640, Japan.ORCID 0000-0001-8454-6155
Showa University · JPKanazawa University · JPShowa University Hospital · JP

Funding

Japan Society for the Promotion of Science JP19K07965Japan Society for the Promotion of Science JP19K11698Japan Society for the Promotion of Science JP26461266
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that leads to progressive cognitive decline. Several effective natural components have been identified for the treatment of AD. However, it is difficult to obtain conclusive evidence on the safety and effectiveness of natural components, because a variety of factors are associated with the progression of AD pathology. We hypothesized that a therapeutic effect could be achieved by combining multiple ingredients with different efficacies. The purpose of this study was thus to evaluate a combination treatment of curcumin (Cur) and ferulic acid (FA) for amyloid-β (Aβ)-induced neuronal cytotoxicity. The effect of Cur or FA on Aβ aggregation using thioflavin T assay was confirmed to be inhibited in a concentration-dependent manner by Cur single or Cur + FA combination treatment. The effects of Cur + FA on the cytotoxicity of human neuroblastoma (SH-SY5Y) cells induced by Aβ exposure were an increase in cell viability, a decrease in ROS and mitochondrial ROS, and repair of membrane damage. Combination treatment showed an overall higher protective effect than treatment with Cur or FA alone. These results suggest that the combined action mechanisms of Cur and FA may be effective in preventing and suppressing the progression of AD.

Indexed as

Alzheimer DiseaseCurcuminNeuroblastomaNeurodegenerative DiseasesNeuroprotective AgentsNeurotoxicity SyndromesAmyloid beta-PeptidesCell Line, TumorCoumaric AcidsHumansReactive Oxygen SpeciesAmyloid beta-PeptidesCoumaric AcidsCurcuminferulic acidNeuroprotective AgentsReactive Oxygen SpeciesAlzheimer’s diseaseamyloid-βcurcuminferulic acidneurotoxicityoxidative stress

Identifiers

PMID36077082
PMCPMC9456505
OpenAlexW4293537969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.